《新股消息》药明巨诺(02126.HK)公开发售超购448倍 一手中签率仅5%
由药明康德(02359.HK)及美国医药研发平台Juno共同投资、内地临床及临床前阶段细胞治疗公司药明巨诺(02126.HK)公布招股结果,计划发行9,769.2万股,公开发售录超购448.42倍,据国际发售初步提呈发售的发售股份已获超额认购(相当国际发售初步可供认购的发售股份总数约28.5倍),经重新分配後,公开发售股数增至50%,一手500股中签率为5%
每股发售价定於23.8元,为上限定价(招股价介乎20至23.8元)。该股将於明日(3日)挂牌上市。高盛及瑞银为联席保荐人。
该股引入10名基石投资者,共认购4,884万股份,包括Rock Springs Capital、橡树资本管理公司等各认购651.2万股;高瓴基金、太平资产管理等各认购325.6万股。
公司预计集资净额为21.97亿元,当中30%将用於有关relma-cel的研发活动;10%用於建立专门的内部销售与营销团队将relma-cel推广至中国各地;6%用於有关JWCAR129的研发活动;28%用於有关其他临床前候选产品;4%用於透过行使Acepodia选择权获得Acepodia许可;12%将用於新潜在收购及引进授权机会;余下10%为营运资金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.